Fluoxetine

Fluoxetine is a medicine of the selective serotonin reuptake inhibitor family, a group of antidepressants that raise the availability of the neurotransmitter serotonin in the brain ^[1][2]. Chemically it is a fluorinated compound, sold as a racemic mixture of two mirror-image forms, with the molecular formula C17H18F3NO ^[1]. It is well absorbed by mouth and is broken down in the liver into an active metabolite called norfluoxetine; both the parent drug and this metabolite linger for a long time, with elimination measured in days to weeks rather than hours, which gives fluoxetine one of the longest durations of action among antidepressants and makes withdrawal symptoms less abrupt when it is stopped ^[3].

The drug grew out of research begun at the American company Eli Lilly around 1970, as the idea took hold that boosting serotonin signalling could relieve depression ^[2]. Chemists including Bryan Molloy and Ray Fuller, together with the pharmacologist David Wong, identified fluoxetine as the most selective serotonin reuptake inhibitor in their series ^[2]. First reported in the mid-1970s and given the trade name Prozac, it was approved by the United States Food and Drug Administration in 1987 and reached the American market the following year ^[1][2]. It went on to become one of the most widely prescribed medications in the world and a cultural landmark, and it remains on the World Health Organization's List of Essential Medicines ^[1].

Fluoxetine is approved for a broad range of psychiatric conditions, including major depressive disorder in adults and in children from the age of eight, obsessive-compulsive disorder, panic disorder, bulimia nervosa, and premenstrual dysphoric disorder ^[1]. A large network meta-analysis comparing twenty-one antidepressants found that all of them, fluoxetine included, were more effective than placebo for acute depression in adults, and that fluoxetine was among the better-tolerated options, with relatively few patients stopping treatment ^[4]. It is also used off-label for other anxiety-related conditions ^[1].

Common side effects include nausea, sleep disturbance, headache, and sexual difficulties, and fluoxetine is often regarded as one of the more activating SSRIs, sometimes causing restlessness or insomnia ^[1][3]. Combining it with other serotonin-raising drugs, especially monoamine oxidase inhibitors, can trigger a potentially dangerous reaction known as serotonin syndrome, and because it strongly inhibits the liver enzymes CYP2D6 and CYP2C19 it can alter the levels of many other medicines ^[1][3]. Like other antidepressants, its labelling carries a warning that it may increase suicidal thoughts in children, adolescents, and young adults, particularly early in treatment, so use in younger patients calls for close monitoring ^[1]. It is supplied as capsules, tablets, and a liquid ^[1].

Fluoxetine is an SSRI with common effects including nausea, insomnia or activation and anxiety, appetite changes, and sexual dysfunction; its long half-life makes classic discontinuation syndrome less pronounced but prolongs the window for drug interactions. It is a potent CYP2D6 inhibitor and can cause serotonin syndrome when combined with other serotonergic agents or MAOIs. Like all antidepressants it carries a boxed warning for increased suicidal thinking in children and young adults, so mood changes warrant monitoring early in treatment.

Fluoxetine inhibits cytochrome P450 2D6 and 3A4, causing significant pharmacokinetic interactions with many drugs. The combination of fluoxetine with warfarin increases the international normalized ratio; however, large-scale pharmacovigilance analysis suggests the actual bleeding risk in clinical practice is lower than theoretical predictions, though elevation of INR remains a real phenomenon ^[5].

Fluoxetine is contraindicated with monoamine oxidase inhibitors; the combination produces serotonin syndrome with neuromuscular and autonomic symptoms and has caused severe, life-threatening reactions ^[6]. Concurrent caffeine consumption alters fluoxetine pharmacokinetics by decreasing renal clearance and prolonging drug action, potentially augmenting antidepressant effects ^[7]. Most common pairings with other selective serotonin reuptake inhibitors, atypical antipsychotics, and anticonvulsants have not been systematically studied for interaction magnitude.

Checking a whole stack? Run it through interactions + stacks.

Fluoxetine was developed at Eli Lilly and Company in the early 1970s by a research team that included David Wong, Bryan Molloy, Ray Fuller, and Klaus Schmiegel, who were searching for a compound that would block serotonin reuptake without the broad receptor activity of the older tricyclic antidepressants. Working from a chemical scaffold related to the antihistamine diphenhydramine, they identified the molecule then known as LY110140 in 1972 and confirmed its selective action on the serotonin transporter.

After a lengthy development and review process it was approved in the United States in 1987 and launched the following year under the brand name Prozac. It became the first genuinely successful selective serotonin reuptake inhibitor and a cultural landmark, inspiring books such as Listening to Prozac and helping to make the SSRIs the dominant treatment for depression. It is now a widely available generic and appears on the World Health Organization's List of Essential Medicines.

Fluoxetine is widely credited with transforming the treatment of depression, offering comparable efficacy to the older tricyclics while being far safer in overdose and generally easier to tolerate, a combination that helped bring antidepressant treatment into mainstream practice. It carries a strong evidence base across major depression, obsessive-compulsive disorder, bulimia, and premenstrual dysphoric disorder, and its unusually long half-life gives it a practical advantage: missed doses matter less and discontinuation symptoms are milder than with shorter-acting SSRIs.

Honest discussion acknowledges that it can take several weeks to reach full effect, that sexual side effects and early activation or restlessness are common complaints, and that regulators require a warning about suicidal thinking in younger patients. Even so, decades of clinical experience have made it one of the most trusted and thoroughly studied psychiatric medicines, and for many prescribers it remains a sensible first choice.